Clinical observation of chlorpromazine hydrochloride combined with palonosetron in preventing nausea and vomiting induced by chemotherapy drugs

Objective To explore the clinical effect of chlorpromazine hydrochloride combined with palonosetron in preventing nausea and vomiting induced by chemotherapy drugs. Methods Patients(126 cases) with malignant tumor receiving emetogenic chemotherapy in Xiangyang Central Hospital from January 2014 to July 2014 were randomly divided into control and treatment groups, and each group had 63 cases. The patients in the control group were iv administered with Palonosetron Hydrochloride Injection 30 min before chemotherapy at the first day of the chemotherapy, 0.25 mg/time, once daily, and the injection time was more than 30 s. The patients in the treatment group were im administered with Chlorpromazine Hydrochloride Injection at the basis of the control group, 25 mg/time. One course of treatment was 3 weeks, the control rates of nausea and vomiting were observed after one chemotherapy cycle. Results The acute vomiting control rates in the control and treatment groups were 76.19% and 84.13%, respectively, while delayed vomiting control rates in two groups were 50.79% and 63.49%, respectively. The acute and delayed vomiting control rates in treatment group were higher than those in the control group, and there were differences between two groups(P 0.05). The acute nausea control rates in the control and treatment groups were 58.73% and 77.78%, respectively, while delayed nausea control rates in two groups were 49.21% and 65.08%, respectively, and there were differences between two groups(P 0.05). The acute nausea control rates in the control and treatment groups were 87.30% and 90.48%, respectively, while delayed nausea control rates in two groups were 84.12% and 87.30%, respectively, and there was no difference between two groups. Conclusion Chlorpromazine hydrochloride combined with palonosetron has the good clinical effect in preventing nausea and vomiting induced by chemotherapy drugs, and will not increase adverse reactions, which is worth clinical promotion.